{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:57:29Z","timestamp":1785585449569,"version":"3.56.0"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015542","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1002\/ajh.70408","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:17:09Z","timestamp":1781324229000},"page":"2435-2440","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third\u2010Line or Later Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1002","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Blavatnik Family Chelsea Medical Center, Mount Sinai  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Efebera","sequence":"additional","affiliation":[{"name":"Division of Blood and Marrow Transplant OhioHealth  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habte","family":"Yimer","sequence":"additional","affiliation":[{"name":"Texas Oncology\u2010Tyler  Tyler Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Shukla","sequence":"additional","affiliation":[{"name":"Evidera, a Business Unit of PPD, Part of Thermo Fisher Scientific  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venediktos","family":"Kapetanakis","sequence":"additional","affiliation":[{"name":"Evidera, a Business Unit of PPD, Part of Thermo Fisher Scientific  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Purser","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Boytsov","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Ballew","sequence":"additional","affiliation":[{"name":"GSK  Upper Providence Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"e_1_2_1_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422"},{"key":"e_1_2_1_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x"},{"key":"e_1_2_1_10_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2514663"},{"key":"e_1_2_1_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00653-9"},{"key":"e_1_2_1_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00330-4"},{"key":"e_1_2_1_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201044"},{"key":"e_1_2_1_10_8_1","doi-asserted-by":"crossref","unstructured":"E. C.Watson H. A.Shuwa M.Heycock et\u00a0al. Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma via Inflammatory and Immunogenic Cell Death. medRxiv. 2025:2025.2009.2011.25335116.","DOI":"10.1101\/2025.09.11.25335116"},{"key":"e_1_2_1_10_9_1","unstructured":"Food and Drug Administration \u201cBlenrep Prescribing Information\u201daccessed March 4 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761440s000lbl.pdf."},{"key":"e_1_2_1_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090"},{"key":"e_1_2_1_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27661"},{"key":"e_1_2_1_10_12_1","unstructured":"Food and Drug Administration \u201cEmpliciti Prescribing Information\u201daccessed March 4 2026 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761035s015lbl.pdf."},{"key":"e_1_2_1_10_13_1","unstructured":"Food and Drug Administration Abecma Prescribing Informationaccessed March 4 2026 https:\/\/packageinserts.bms.com\/pi\/pi_abecma.pdf."},{"issue":"7","key":"e_1_2_1_10_14_1","first-page":"2337","article-title":"Belantamab Mafodotin: An Important Treatment Option for Vulnerable Patients With Triple Class Exposed Relapsed and\/or Refractory Multiple Myeloma","volume":"109","author":"Mateos M. V.","year":"2024","journal-title":"Haematologica"},{"key":"e_1_2_1_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2023.09.004"},{"key":"e_1_2_1_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8084"},{"key":"e_1_2_1_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2504318"},{"key":"e_1_2_1_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.70168"},{"key":"e_1_2_1_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2021.1855143"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.70408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.70408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T11:19:34Z","timestamp":1785583174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.70408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ajh.70408"],"URL":"https:\/\/doi.org\/10.1002\/ajh.70408","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"2026-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}